Table 3

Success rates for the clinical and bacteriological responses in the two study arms

CiprofloxacinImipenemp value3-150 (95% CI)
Clinical response:
 Success rate29/41 (71%)27/34 (79%)0.435 (–10.8 to 28.1)
  Cure17/41 (42%)22/34 (65%)
  Improvement12/41 (29%)5/34 (14%)
Pseudomonas aeruginosa(n=26)
  Success rate10/14 (71%)8/12 (67%)1.0 (–40.4 to 30.9)
 Enterobacteriaceae (n=9)
  Success rate5/6 (83%)2/3 (67%)1.0 (–77.8 to 44.4)
Bacteriological response:
 Success20/41 (49%)17/34 (50%)1.0 (–21.5 to 23.9)
  Eradication7/41 (17%)10/34 (29%)
  Presumed eradication13/41 (32%)7/34 (21%)
 Failure21/41 (51%)17/34 (50%)
  Persistence2/41 (5%)8/34 (24%)
  Superinfection9/41 (22%)5/34 (15%)
  Presumed failure10/41 (24%)4/34 (11%)
 Pseudomonas aeruginosa(n=26)
  Success rate7/14 (50%)3/12 (25%)0.247 (–60.9 to 10.9)
 Enterobacteriaceae (n=9)
  Success rate5/6 (83%)1/3 (33%)0.266 (–111.1 to 11.1)
  • In addition, subanalysis of patients withPseudomonas aeruginosa and Enterobacteriaceae in baseline culture are shown.

  • 3-150 p values calculated using χ2 test.